Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of autologous dendritic cell HIV vaccine during stable HAART
NL-OMON25488Phase 2Active, not recruiting
- Sponsor
- Erasmus MC, Rotterdam, Vrije Universiteit Brussel, Brussel K. Thielemans, MD, PhD Director Laboratory of Molecular and Cellular Therapy Medical School Vrije Universiteit Brussel Laarbeeklaan 103 B-1090 Brussels Tel: + 32 (0)2 477 45 69 Fax: + 32 (0)2 477 45 68 e-mail: [email protected]
- Start
- Dec 2006
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous dendritic cells electroporated with HIV-1 tat mRNA, autologous dendritic cells electroporated with HIV-1 Rev mRNA and autologous dendritic cells electroporated with HIV-1 Nef mRNA in Human immunodeficiency virus infection type 1, sponsored by Erasmus MC, Rotterdam, Vrije Universiteit Brussel, Brussel K. Thielemans, MD, PhD Director Laboratory of Molecular and Cellular Therapy Medical School Vrije Universiteit Brussel Laarbeeklaan 103 B-1090 Brussels Tel: + 32 (0)2 477 45 69 Fax: + 32 (0)2 477 45 68 e-mail: [email protected]. Started Dec 2006; status: active, not recruiting.
02
Drugs
autologous dendritic cells electroporated with HIV-1 tat mRNAautologous dendritic cells electroporated with HIV-1 Rev mRNAautologous dendritic cells electroporated with HIV-1 Nef mRNA
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON25488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25488.